Dung T. Le, MD, of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, and Axel Grothey, MD, of the Mayo Clinic, discuss how mismatch repair status predicts clinical benefit of immune checkpoint blockade with pembrolizumab (Abstract LBA100).
James L. Mulshine, MD, of Rush University Medical Center, and David E. Gerber, MD, of The University of Texas Southwestern Medical Center, discuss the ALCHEMIST tr...
Clifford A. Hudis, MD, and Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, discuss the use of the decision support system Watson for Oncology and...
John Smyth, MD, of the University of Edinburgh, discusses oncology from an international point of view.
Leonard Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses how the cost of care affects behavior and decision-making on the part of patients and oncologists.
Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital NHS Trust, discusses fulvestrant and palbociclib as a treatment option in pre- and postmenopausal women with hormone rece...
